Globally, 20 million new cancer cases have been reported in 2023 alone, and hypoxia is a hallmark of all types of solid cancers. Considering 40% of these patients are diagnosed with solid hypoxic tumors and HYPOXYCIN-1 offers a precision imaging and treatment solution for such tumors, this product potentially creates a global yet untapped market opportunity for managing many types of cancer.
WWiKY’s products include Hypoxycin-1™, a product currently approved by Health Canada for a Phase I/II clinical trial, Hypoxycin- M™, a cell hypoxia imaging agent, Hypoxycin-P™, a synthon for synthesizing radiolabeled Hypoxycin-1 (PET or SEPECT), and a pipeline of next generation ligand-based theranostics and nanotheranostics in collaboration with renowned scientists.
The following market projection reflects a conservative approach for one of our products, Hypoxycin-1™ – initially targeting only 0.5 % of the 54,000 patients in the US alone that are diagnosed with hypoxic tumors in only one cancer condition – oral and pharyngeal cancer. Three years’ projection is based on the per dose costs charged for similar radiopharmaceuticals used to treat other cancer conditions. 1
1CA: A Cancer J for Clinicians. https://doi.org/10.3322/caac.21654
